-
MCRS1 Enhances MHC-I–Dependent Tumor Immunity
2026-08-14
The reference study identifies MCRS1 as a transcriptional regulator that increases MHC-I expression and sensitizes pancreatic tumors to T cell–mediated killing and α-PD-1 therapy. Its CRISPR activation, mechanistic, animal, and patient-level evidence connects chromatin regulation with tumor antigen presentation, while also highlighting practical requirements for preserving protein integrity in related validation workflows.
-
Protease Inhibitor Cocktail for p53 Assays
2026-08-13
Discover how a Protease Inhibitor Cocktail can preserve fragile p53-Y220C samples without chelating divalent cations. This guide connects protein extraction protease inhibitor selection with structure-guided mutant-p53 reactivation assays and practical interpretation of degradation-sensitive data.
-
Lassa Virus Spike Conformational Changes and Inhibition
2026-08-13
Katz et al. define how endosomal acidification reshapes the Lassa virus spike before membrane fusion, linking early transmembrane remodeling to later receptor release and spike opening. Their structure-guided analysis of ARN-75039 provides a molecular explanation for entry inhibition and identifies conformational transitions that may guide antiviral research.
-
Vardenafil HCl Trihydrate: Assay Guide
2026-08-12
This scenario-based guide explains how Vardenafil HCl Trihydrate (SKU A4323) can support interpretable PDE5, cGMP, proliferation, and cytotoxicity experiments. It focuses on concentration logic, solvent compatibility, assay controls, proteoform-aware interpretation, and practical product-selection criteria.
-
Lassa Virus Spike: pH-Driven Entry and Inhibition
2026-08-12
The reference study maps how acidification reorganizes the Lassa virus spike before membrane fusion, identifying early transmembrane changes, pH-sensitive metal coordination, and later spike opening that promotes receptor release. Structural analysis combined with functional inhibition by ARN-75039 provides a mechanistic framework for understanding LASV entry and targeting related viral fusion processes.
-
Protease Inhibitor Cocktail for HepaRG Assays
2026-08-11
Learn how a Protease Inhibitor Cocktail can protect HepaRG-derived proteins without chelating divalent cations. This guide connects protease control to HBV/HDV assay design, differentiation state, and interpretation of biochemical endpoints.
-
Radioiodinated Balsalazide for UC Imaging in Mice
2026-08-11
Sanad et al. developed and evaluated radioiodinated balsalazide as a colon-directed tracer for ulcerative colitis in mice. The optimized chloramine-T labeling workflow produced a stable radiotracer and showed markedly elevated uptake in ulcerated colon, supporting its use for preclinical biodistribution and inflammatory bowel disease model studies.
-
OTUD3-SLC7A11 Drives Ferroptosis Resistance in ccRCC
2026-08-10
The 2025 Cancer Letters study identifies OTUD3 as a deubiquitinase that stabilizes SLC7A11, lowers oxidative pressure, and enables clear cell renal cell carcinoma cells to resist sunitinib-induced ferroptosis. Its mechanistic framework links protein turnover to cystine metabolism and suggests that OTUD3–SLC7A11 activity may be a useful therapeutic and biomarker axis for studying tyrosine kinase inhibitor resistance.
-
ZNF263–ULK1 Autophagy Axis in ICC
2026-08-09
Yan and colleagues identify ZNF263 as a transcriptional driver of intrahepatic cholangiocarcinoma (ICC) proliferation and connect its activity to enhancer-mediated activation of ULK1 and autophagy. By combining clinical tissue analysis, genomic profiling, reporter validation, cellular assays, and xenograft experiments, the study provides a mechanistic framework for interpreting ZNF263 as a potential prognostic or therapeutic target.
-
L-Ornithine and the Liver–Brain Axis
2026-08-08
L-Ornithine is more than a urea cycle intermediate. Emerging evidence positions ornithine as a mechanistic bridge between hepatic OTC dysfunction, systemic nitrogen handling, astrocyte glycolysis, and CNS toxicity. This article outlines how translational researchers can use L-Ornithine to build more informative metabolic enzyme assays and liver–brain axis models.
-
Poly (I:C) Workflow for Innate Immune Assays
2026-08-07
Build reproducible interferon, dendritic-cell, and cardiomyocyte stress assays with Poly (I:C), a controllable dsRNA stimulus rather than a replicating pathogen. The workflow also shows how a 2024 cardiomyocyte study can guide route selection, controls, and interpretation of dsRNA-sensing experiments.
-
Bardoxolone Methyl: Precision Redox Modulation in Disease Mo
2026-08-07
Bardoxolone methyl (CDDO methyl ester) empowers researchers to precisely modulate the Nrf2 and NF-kB signaling pathways for advanced oxidative stress and inflammation studies. This guide details protocol enhancements, troubleshooting tactics, and translational insights drawn from recent breakthroughs in redox system biology, offering a practical edge for bench scientists.
-
Tunable Human Intestinal Organoids: Balancing Stemness and D
2026-08-06
This study introduces a human intestinal organoid system that achieves a controlled equilibrium between stem cell self-renewal and differentiation, overcoming previous limitations of cellular homogeneity and limited scalability. The optimized approach enables enhanced cell diversity and proliferative capacity, offering a robust platform for disease modeling and high-throughput applications.
-
Bay 11-7821 in Cancer Immunology: Mechanisms and Strategy
2026-08-06
Explore how Bay 11-7821 (BAY 11-7082) is revolutionizing translational research at the interface of inflammation, apoptosis, and immune modulation. This article offers mechanistic depth and practical strategy for deploying Bay 11-7821 in workflows addressing cancer immune resistance, with direct reference to recent breakthroughs in radiotherapy-immunotherapy synergy and advanced NF-κB pathway interrogation.
-
IGF2BP1-m6A-TUBB4B Axis Drives Hepatic Stellate Cell Activat
2026-08-05
This study identifies the m6A reader IGF2BP1 as a key regulator of hepatic stellate cell (HSC) activation, acting through stabilization of TUBB4B mRNA in an m6A-dependent manner. Targeting the IGF2BP1/TUBB4B/FAK axis emerges as a promising therapeutic strategy for liver fibrosis, with implications for advancing antifibrotic research.